TrialThoracic cancer2021

Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial.

Daijiro Harada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.